Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer

Researchers identified that YES1 was the most highly overexpressed Src family kinase in triple negative breast cancer and was associated with poor patient outcomes.